1. News | 2020.04.15

   COVID-19 - The Bioinformatics and Biostatistics Hub on the front line

   Like many other research teams at the Institut Pasteur, the Bioinformatics and Biostatistics Hub is engaged in fighting against the COVID-19 pandemic by participating in the curation of GISAID data (Global Initiative on Sharing All Influenza Data). The Hub is the service division of the Computational Biology Department, and is composed of 50 experts in biostatistics and bioinformatics.At the end...

2. Page avancée | 2020.06.17

   All SARS-CoV-2 / COVID-19 from the Institut Pasteur

   All SARS-CoV-2 / COVID-19 from the Institut Pasteur

3. Vidéo | 2020.02.20

   COVID-19 : What we have learnt as of 20 February 2020

   COVID-19 : What we have learnt as of 20 February 2020

4. Article | 2020.06.22

   Fiche maladie redirect en Sars-CoV-2 / Covid-19

   Fiche maladie redirect en Sars-CoV-2 / Covid-19

5. Article | 2020.07.07

   COVID-19 - The Bioinformatics and Biostatistics Hub on the front line

   COVID-19 - The Bioinformatics and Biostatistics Hub on the front line

6. News | 2023.02.20

   Two effective new antiviral drugs for SARS-CoV-2

   Scientists at the Institut Pasteur have successfully synthesized two novel molecules that are active against several variants of the virus responsible for COVID-19. The discovery could inspire new families of antiviral drugs against future emerging viral diseases.

7. Événement | 2021.10.07

   COVID-19, cancers, antibiotic resistance: meet the researchers at the Institut Pasteur

   On the occasion of the 15th edition of the Pasteurdon, join the Institut Pasteur, on Thursday, October 7, in partnership with Figaro Partner, for an online program on the major current public health issues: COVID-19, cancers, antibiotic resistance. See you on October 7 on the Pasteurdon website.

8. News | 2021.10.18

   "COVID-19, cancers and antibiotic resistance: meeting the researchers of the Institut Pasteur": programme available for replay

   For the opening of the Pasteurdon 2021, scientists from the Institut Pasteur took part in a digital programme looking at some of the major current issues in medical research, "COVID-19, cancers and antibiotic resistance: meeting Institut Pasteur researchers", in partnership with Figaro Partner. Watch online (in French).

9. Document de presse | 2020.03.19

   CEPI collaborates with the Institut Pasteur in a consortium to develop Covid-19 vaccine

   Consortium to be led by the Institut Pasteur and will include Themis and the University of Pittsburgh.CEPI to provide initial US$4.9 million for consortium to develop a Covid-19 vaccine candidate based on measles-vector technology.Partnership becomes eighth Covid-19 vaccine development project that CEPI has signed since Jan 23, 2020 OSLO, NORWAY, March 19, 2020 – CEPI, the Coalition for...

10. News | 2021.05.06

    Creation of the startup SPIKIMM to develop monoclonal antibodies as an innovative treatment for Covid-19

    The Institut Pasteur has recently signed an exclusive worldwide license agreement with the new biotech start-up SpikImm SAS, created by Truffle Capital, for the development of anti-SARS-CoV-2 (Covid-19) monoclonal antibodies for therapeutic and diagnostic use.Monoclonal antibody therapy is one of the most innovative ways currently available to treat Covid-19 patients and prevent severe forms of...

Pages